FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Delta 9 Cannabis Inc. Stock AnalysisComprehensive stock analysis for Delta 9 Cannabis Inc. (DN.TO) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisDN.TO
DN.TO
Delta 9 Cannabis Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
DN.TO
Home🔹Stocks🔹Delta 9 Cannabis Inc.

Delta 9 Cannabis Inc.

🇨🇦DN.TO•TSX

Delta 9 Cannabis Inc.

🇨🇦DN.TO•TSX
Market cap
$1.51M
Sentiment

Your view on DN.TO

Mkt Cap
$1.51M
Sentiment
Your view
DN.TO
Delta 9 Cannabis Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
DN.TO
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Delta 9 Cannabis Inc.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
John William Arbuthnot IV
Headquarters
CA
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
John William Arbuthnot IV
Headquarters
CA
Description

Delta 9 Cannabis Inc. operates as an integrated cannabis company. The company, through its subsidiary, Delta 9 Bio-Tech Inc., engages in the cultivation, processing, extraction, wholesale distribution, retail, and sale of medical and recreational cannabis products.

Its products include dried cannabis flowers, pre-rolls, decontamination pods, and dried sift cannabis, as well as oils, and extracted and derivative products. The company also offers grow pods and live plants to other licensed and pre-licensed companies.

In addition, it operates as a medical clinic that provides physician consultation services to patients seeking a medical recommendation for a cannabis prescription.

As of April 20, 2022, the company owned and operated 35 retail stores under the Delta 9 brand name across the Canadian Prairies. Delta 9 Cannabis Inc. was incorporated in 2001 and is headquartered in Winnipeg, Canada.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Delta 9 Cannabis Inc., and the rating behind it. DN.TO last traded at C$0.0050; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Delta 9 Cannabis Inc.. Starting points for Delta 9 Cannabis Inc.: EPS -C$0.10, beta 1.21 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Delta 9 Cannabis Inc.. Delta 9 Cannabis Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Delta 9 Cannabis Inc.. Trailing twelve-month EPS for Delta 9 Cannabis Inc. stands at -C$0.10. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Delta 9 Cannabis Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Delta 9 Cannabis Inc. valued side by side against its closest peers. Delta 9 Cannabis Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Delta 9 Cannabis Inc., and how their positions are changing. At a C$1.5M market value, institutional positions materially move Delta 9 Cannabis Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Delta 9 Cannabis Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Delta 9 Cannabis Inc.. Delta 9 Cannabis Inc. is a C$1.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Delta 9 Cannabis Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Delta 9 Cannabis Inc.. Coverage tracks Delta 9 Cannabis Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

More Drug Manufacturers - Specialty & Generic companies

  • RVVTF — Revive Therapeutics Ltd.
  • RWB.CN — Red White & Bloom Brands Inc.
  • RXEI — RxElite, Inc.
  • SAGD — South American Gold Corp.
  • SBFM — Sunshine Biopharma, Inc.
  • SBFMW — Sunshine Biopharma, Inc.
  • SDZNY — Sandoz Group AG
  • SESI — SES Solar Inc.
  • SFOSF — Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • SFWJ — Software Effective Solutions Corp.
  • SGFEF — Siegfried Holding AG
  • SGIOF — Shionogi & Co., Ltd.

News

Latest Market News